BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35240234)

  • 1. DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.
    Zhou Y; Guan L; Li W; Jia R; Jia L; Zhang Y; Wen X; Meng S; Ma D; Zhang N; Ji M; Liu Y; Ji C
    Cancer Lett; 2022 May; 533():215608. PubMed ID: 35240234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
    Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
    Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
    Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
    Liu S; Breit S; Danckwardt S; Muckenthaler MU; Kulozik AE
    Ann Hematol; 2009 Jul; 88(7):613-21. PubMed ID: 19057901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
    Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
    Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome.
    Pui CH
    Cancer Cell; 2009 Feb; 15(2):85-7. PubMed ID: 19185842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
    López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
    Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.
    Real PJ; Ferrando AA
    Leukemia; 2009 Aug; 23(8):1374-7. PubMed ID: 19357700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
    Meyer LK; Delgado-Martin C; Sharp PP; Huang BJ; McMinn D; Vincent TL; Ryan T; Horton TM; Wood BL; Teachey DT; Taunton J; Kirk CJ; Hermiston ML
    Br J Haematol; 2022 Jul; 198(1):137-141. PubMed ID: 35434798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
    Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
    J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.
    Liu Y; Ge J; Li Q; Guo X; Gu L; Ma ZG; Li XH; Zhu YP
    Leuk Lymphoma; 2014 Sep; 55(9):2179-88. PubMed ID: 24597985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
    Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
    Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antileukemic therapies in
    Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor.
    Liang YN; Tang YL; Ke ZY; Chen YQ; Luo XQ; Zhang H; Huang LB
    J Steroid Biochem Mol Biol; 2017 Sep; 172():62-68. PubMed ID: 28578002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to γ-secretase inhibition.
    Hounjet J; Habets R; Schaaf MB; Hendrickx TC; Barbeau LMO; Yahyanejad S; Rouschop KM; Groot AJ; Vooijs M
    Oncogene; 2019 Jul; 38(27):5457-5468. PubMed ID: 30967635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
    Palomero T; Ferrando A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia.
    Kaushik B; Pal D; Saha S
    Curr Drug Targets; 2021; 22(15):1789-1798. PubMed ID: 33538669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.